Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 24, 2012. The report details a specific share repurchase transaction executed in accordance with shareholder authority granted at the Annual General Meeting on May 3, 2012.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,000,000 Ordinary Shares of 25 pence each.
- Purchase Date: October 24, 2012.
- Price Range: Highest price paid was 1,413.5 pence per share; lowest price paid was 1,403 pence per share.
- Treasury Holdings (Settled): 510,790,427 shares (9.38% of total issued share capital).
- Treasury Holdings (Including Unsettled): 514,190,427 shares (10.42% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,934,490,785 shares.
Material Changes
The primary material change is the reduction of outstanding shares through the purchase of 1,000,000 shares, which were intended to be held in Treasury. This transaction increased the percentage of total voting rights held in Treasury from the prior settled position to 10.42% when including unsettled shares.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on operational outlook, or discussion of risks and contingencies. It is a compliance disclosure confirming conformity with the Financial Services Authority's Disclosure and Transparency Rules and explicitly states it does not constitute an offer to purchase or subscribe for securities.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (510,790,427 settled) against the company's latest annual report.
- Confirm the calculation of total voting rights (4,934,490,785 shares in issue) for disclosure threshold assessments.
- Review the remaining authorization for share repurchases under the mandate granted on May 3, 2012.
- Check subsequent filings for the settlement status of the 3,400,000 shares included in the "including shares which have been purchased but not yet settled" figure.